A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 20 Sep 2024
At a glance
- Drugs Axatilimab (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Syndax Pharmaceuticals
- 27 Feb 2024 According to a Syndax Pharmaceuticals media release, enrollment is ongoing in this study.
- 02 Jan 2024 According to a Syndax Pharmaceuticals media release, Status changed from not yet recruiting to recruiting.
- 17 Nov 2023 Status changed from planning to not yet recruiting.